The Prospects of an Active Vaccine Against Asthma Targeting IL-5

Allergen-specific T helper type 2 (Th2) responses followed by eosinophilic inflammation of the lung are important causes of allergic asthma. Interleukin-5 (IL-5) is a master regulator of eosinophil differentiation as well as activation. Blocking IL-5 using monoclonal antibodies (mAbs) against IL-5 i...

Full description

Bibliographic Details
Published in:Frontiers in Microbiology
Main Authors: Martin F. Bachmann, Aadil El-Turabi, Antonia Fettelschoss-Gabriel, Monique Vogel
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Subjects:
virus-like particle
IL-5
vaccine
asthma
cytokine
vaccination
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2018.02522/full
Description
Summary:Allergen-specific T helper type 2 (Th2) responses followed by eosinophilic inflammation of the lung are important causes of allergic asthma. Interleukin-5 (IL-5) is a master regulator of eosinophil differentiation as well as activation. Blocking IL-5 using monoclonal antibodies (mAbs) against IL-5 is a powerful way to improve asthmatic symptoms in patients with an eosinophilic component of the disease. We have previously shown that vaccination against IL-5 can abrogate eosinophilic inflammation of the lung in allergic mice. More recently, we have demonstrated that eosinophil-mediated skin disease in horses with insect bite hypersensitivity can be strongly reduced by vaccination against IL-5. Here we would like to propose the development of a similar vaccine for the treatment of asthma in humans.
ISSN:1664-302X

Similar Items